Beneficial effects of combining a Type II ATP competitive inhibitor with an allosteric competitive inhibitor of Bcr-Abl for the treatment of imatinib-sensitive and imatinib resistant CML

समान संसाधन

• Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL(+) leukemias
  द्वारा: Weisberg, Ellen, और अन्य
  प्रकाशित: (2007)
• Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
  द्वारा: Deng, Xianming, और अन्य
  प्रकाशित: (2010)
• The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR–ABL
  द्वारा: Hantschel, Oliver, और अन्य
  प्रकाशित: (2012)
• A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
  द्वारा: Gumireddy, Kiranmai, और अन्य
  प्रकाशित: (2005)
• Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
  द्वारा: Jabbour, Elias, और अन्य
  प्रकाशित: (2012)